236 related articles for article (PubMed ID: 19380522)
1. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
[TBL] [Abstract][Full Text] [Related]
2. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
[TBL] [Abstract][Full Text] [Related]
3. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
4. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
[TBL] [Abstract][Full Text] [Related]
5. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract][Full Text] [Related]
6. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
[TBL] [Abstract][Full Text] [Related]
7. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
8. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM; Christensen BC
Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
Farahani MS; Shahbazi S; Moghaddam SA; Mahdian R
Reprod Sci; 2015 Jun; 22(6):679-84. PubMed ID: 25361550
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
Nelson HH; Christensen BC; Plaza SL; Wiencke JK; Marsit CJ; Kelsey KT
Lung Cancer; 2010 Jul; 69(1):51-3. PubMed ID: 19854534
[TBL] [Abstract][Full Text] [Related]
11. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
[TBL] [Abstract][Full Text] [Related]
12. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ
Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817
[TBL] [Abstract][Full Text] [Related]
13. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.
Li ZH; Pan XM; Han BW; Guo XM; Zhang Z; Jia J; Gao LB
Tumour Biol; 2013 Oct; 34(5):3159-63. PubMed ID: 23729275
[TBL] [Abstract][Full Text] [Related]
14. Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma.
Wang WY; Chien YC; Wong YK; Lin YL; Lin JC
Head Neck; 2012 May; 34(5):663-6. PubMed ID: 21688344
[TBL] [Abstract][Full Text] [Related]
15. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.
Grechukhina O; Petracco R; Popkhadze S; Massasa E; Paranjape T; Chan E; Flores I; Weidhaas JB; Taylor HS
EMBO Mol Med; 2012 Mar; 4(3):206-17. PubMed ID: 22307873
[TBL] [Abstract][Full Text] [Related]
18. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
[TBL] [Abstract][Full Text] [Related]
19. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437
[TBL] [Abstract][Full Text] [Related]
20. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
